Corpus Intelligence IC Memo — SHELBY BAPTIST MEDICAL CENTER 2026-04-26 10:37 UTC
IC Memo — SHELBY BAPTIST MEDICAL CENTER
Investment Committee Memorandum | AL | 212 beds | Grade C | EBITDA uplift $11.9M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SHELBY BAPTIST MEDICAL CENTER

CCN 010016 | SHELBY, AL | 212 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

SHELBY BAPTIST MEDICAL CENTER is a 212-bed suburban community hospital in SHELBY, AL with $161.1M in net patient revenue and a -0.9% operating margin. The hospital serves a payer mix of 22.7% Medicare, 10.6% Medicaid, and 66.7% commercial.

Thesis: Undervalued. Our ML models identify $11.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -0.9% to 6.5% (+736bps).

Net Revenue HCRIS$161.1M
Current EBITDA COMPUTED$-1.5M
Operating Margin COMPUTED-0.9%
Occupancy HCRIS50.0%
Revenue / Bed COMPUTED$760K
Net-to-Gross HCRIS10.2%
Distress Probability ML48.4%

2. Market Context & Competitive Position

115
AL Hospitals
-8.5%
State Median Margin
33
Comparable Hospitals

AL has 115 Medicare-certified hospitals with a median operating margin of -8.5%. The target's margin of -0.9% places it above the state median. Among 33 size-comparable peers (106-424 beds), the median margin is -4.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (106-424), prioritizing same-state peers. 33 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SHELBY BAPTIST MEDICAL CENTER (Target)AL212$161.1M-0.9%
THE CHILDRENS HOSPITAL OF ALABAL351$839.5M5.8%
GRANDVIEW MEDICAL CENTERAL404$615.4M14.2%
DCH REGIONAL MEDICAL CENTERAL372$601.9M-11.2%
BAPTIST MEDICAL CENTER SOUTHAL348$595.4M-4.8%
ST VINCENTS BIRMINGHAMAL399$480.0M-5.5%
SOUTHEAST HEALTH MEDICAL CENTEAL353$427.1M-4.4%
EAST ALABAMA MEDICAL CENTERAL297$399.6M-6.5%
USA HEALTH UNIVERSITY HOSPITALAL242$348.5M-6.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $11.9M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$3.4M+210bp18mo
Cost to Collect4.5%2.5%$3.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$3.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.0M+122bp9mo
Clean Claim Rate88.0%96.0%$103K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$3.4M
Cost to Collect
$3.2M
Denial Rate Reduction
$3.2M
A/R Days Reduction
$2.0M
Clean Claim Rate
$103K
Total EBITDA Uplift$11.9M
Current EBITDA$-1.5M
+ RCM Uplift+$11.9M
Pro Forma EBITDA$10.4M
Current Margin-0.9%
Pro Forma Margin6.5%
WC Released (1x)$6.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-2.2M$108.9M0.00x-100.0%
Base (11x exit)10.0x11.0x$-2.2M$119.1M0.00x-100.0%
Bull Case9.0x11.0x$-2.0M$157.5M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-2.0M$171.2M0.00x-100.0%
Bear Case11.0x10.0x$-2.5M$50.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-2.5M$54.6M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 33 hospitals with 106-424 beds
  • Same-state prioritization (n=34)
  • Comp margins: P25=-10.4% / P50=-4.8% / P75=2.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.